SET-NUP214 is a recurrent gamma delta lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | SET-NUP214 is a recurrent gamma delta lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL |
Type de publication | Journal Article |
Year of Publication | 2014 |
Auteurs | Ben Abdelali R, Roggy A, Leguay T, Cieslak A, Renneville A, Touzart A, Banos A, Randriamalala E, Caillot D, Lioure B, Devidas A, Mossafa H, Preudhomme C, Ifrah N, Dombret H, Macintyre E, Asnafi V |
Journal | BLOOD |
Volume | 123 |
Pagination | 1860–1863 |
Date Published | MAR 20 |
Type of Article | Article |
ISSN | 0006-4971 |
Résumé | The SET-NUP214 (TAF1/CAN) fusion gene is a rare genetic event in T-cell acute lymphoblastic leukemia (T-ALL). Eleven (6%) of 196 T-ALL patients enrolled in the French Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) 2003 and 2005 trials harbored a SET-NUP214 transcript. SET-NUP214-positive patients were predominantly (10 [91%] of 11) T-cell receptor (TCR)-negative and strikingly associated with TCR gamma delta lineage T-ALLs, as defined by expression of TCR gamma delta, TCR delta and/or TCR gamma rearrangements but no complete TCR beta variable diversity joining rearrangement in surface CD3/TCR-negative cases. When compared with SET-NUP214-negative patients, SET-NUP214-positive patients showed a significantly higher rate of corticosteroid resistance (91% vs 44%; P = .003) and chemotherapy resistance (100% vs 44%; P = .0001). All SET-NUP214-positive patients but one achieved complete remission, and 9 were allografted. Despite the poor early-treatment sensitivity, the outcome of SET-NUP214-positive patients was similar to that of SET-NUP214-negative patients. |
DOI | 10.1182/blood-2013-08-521518 |